On December 15, 2025, AEON Biopharma, Inc. reported entering into an Exchange Agreement with Daewoong, involving the exchange of $15 million in convertible notes for approximately 23.1 million shares of common stock and warrants, subject to stockholder approval on January 21, 2026.